“We believe that referral for kidney SABR is worthy of consideration in patients with solitary-kidney RCC who are faced with limited and risky management options,” says researcher Rohann Correa, MD, PhD.
Renal Cell Carcinoma
Body mass index appears to be a prognostic factor for treatment outcomes in patients with metastatic renal cell carcinoma, but the direction of the association might vary across treatment modalities.
"Proper patient selection, including those with low-/intermediate-risk disease, is paramount," writes Badar M. Mian, MD.
The authors discuss the case of a 57-year-old man who initially presents to a general surgeon with a chief complaint of right lower back and posterior neck pain, with associated soft tissue swelling. On presentation to the authors' institution, he had experienced regrowth of the masses with "ticking" in the right lumbar area that he correlated with his heartbeat. He also reported unintentional weight loss of 15 pounds over the previous 3 months.
Poll: In an RCC patient with a 4- to 7-cm tumor and no metastasis, which one of the following treatments would you recommend?
Patients with advanced non-clear cell renal cell carcinoma have a high prevalence of germline mutations, including some that could be used to guide therapy.
The finding suggests that, in the setting of a CD117-positive renal tumor biopsy, this modality could reduce patient morbidity and health care costs by avoiding the need for resection in benign cases.
The protein Kidney Injury Molecule 1 shows promise as a blood-based biomarker for renal cell carcinoma diagnosis and for predicting overall survival after RCC diagnosis.
Although it may not be the last word on the topic, new research sheds light on the choice of cytoreductive nephrectomy and/or targeted therapy in patients with metastatic renal cell carcinoma.